Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $116.98 USD
Change Today -4.39 / -3.62%
Volume 835.7K
ALNY On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Michael P. Mason

Vice President of Finance and Treasurer, Alnylam Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 0 board members in 0 different organizations across 1 different industries.

39$345,354
As of Fiscal Year 2014

Background*

Mr. Michael P. Mason has been Vice President of Finance and Treasurer at Alnylam Pharmaceuticals, Inc., since February 28, 2011. Mr. Mason served as Corporate Controller of Alnylam Pharmaceuticals, Inc., from December 2005 to February 2011 and also served as its Senior Director of Finance from August 2009 to February 2011 and as Director of Finance from June 2006 to July 2009. From May 2000 to November 2005, Mr. Mason served in several finance and commercial roles at ...

Read Full Background

Corporate Headquarters*

300 Third Street
Cambridge, Massachusetts 02142

United States

Phone: 617-551-8200
Fax: 617-551-8101

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

MBA
Babson College
Bachelor's Degree
Stetson University

Other Affiliations*

Annual Compensation*

Salary$257,187
Total Annual Compensation$257,187

Stock Options*

All Other Compensation$6,167
Exercised Options20,625
Exercised Options Value$1,773,205
Exercisable Options3,542
Unexercisable Options14,063
Total Value of Options$1,773,205
Total Number of Options38,230

Total Compensation*

Total Annual Cash Compensation$345,354
Total Short Term Compensation$257,187
Other Long Term Compensation$6,167
Total Calculated Compensation$345,354
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $116.98 USD -4.39

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Ali Mortazavi Chief Executive and Director
Silence Therapeutics plc
70.0K GBP
Mark W. Schwartz Ph.D.Chief Executive Officer, President, Director and Member of Ad Hoc (Strategy, Pricing, Etc) Committee
Galena Biopharma, Inc.
$490.0K
Mark Joseph Murray Ph.D.Chief Executive Officer, President and Director
Tekmira Pharmaceuticals Corporation
$377.5K
Kleanthis G. Xanthopoulos Ph.D.Chief Executive Officer, President, Principal Financial & Accounting Officer and Director
Regulus Therapeutics Inc.
$600.0K
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.